NASDAQ: RAPP

Company Deals

Rapport Therapeutics Licenses RAP-219 to Tenacia Bio – $328M Deal Targets Greater China Epilepsy and Bipolar Markets

Fineline Cube Mar 24, 2026

Rapport Therapeutics, Inc. (NASDAQ: RAPP) announced a licensing agreement with Tenacia Biopharmaceuticals (Shanghai) Co., Ltd....

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance